Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Activiomics Extends Agreement with Kyowa Hakko Kirin

Published: Thursday, September 19, 2013
Last Updated: Thursday, September 19, 2013
Bookmark and Share
Activiomics announced it has extended its Contract Research Agreement with Japanese pharmaceutical company Kyowa Hakko Kirin (KHK) by entering into a new research programme.

Activiomics will apply its novel TIQUAS (Targeted In-depth QUAntification of cell Signalling) phosphoproteomics platform to elucidate signalling mechanisms generated by lead compounds supplied by KHK in relevant cell-based systems. This collaboration falls within Activiomics’ strategic partnership with BioFocus.

Activiomics applies innovative mass spectrometry based methods to analyse and interpret cell signalling pathway activity resulting from drug administration and/or disease progression. The company is utilising its technology for the discovery and clinical validation of novel prognostic and predictive biomarkers as well as to provide high-value drug mode of action information for the pharmaceutical and biotechnology industry.

“We have been impressed with the results from the initial stages of our partnership with Activiomics and look forward to working with them on this new programme,” said Hiroshi Okazaki, Ph.D., Managing Officer and Vice President, Head, Research Division, Head, Fuji Research Park at Kyowa Hakko Kirin.

Dr Kevin FitzGerald, CEO of Activiomics, said: “We are delighted to have signed a new contract with Kyowa Hakko Kirin which follows on from a previous successful study. The extension of the partnership is a strong endorsement of the quality and quantity of information that can be generated using our technology platform. We are also grateful to the invaluable support from BioFocus in establishing this collaboration.”

Dr Chris Newton, Managing Director of BioFocus, commented: “We are delighted that the capabilities of our strategic partner, Activiomics, has captured the interest of our client Kyowa Hakko Kirin, and look forward to further synergies from  our alliance with Activiomics.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Activiomics Signs Research Agreement with Kyowa Hakko Kirin
Company signs agreement as part of its strategic partnership with BioFocus.
Friday, November 23, 2012
Activiomics Announces Appointment of Non-Executive Chairman
Dr Trevor Nicholls appointed as Non-executive chairman.
Wednesday, March 28, 2012
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!